Accueil   Agenda - News   Toutes les news MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5

MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5

 

MaaT Pharma Announces DSMB Approval to Proceed to Cohort 4 out of 5 in Phase 1b CIMON Trial Testing Capsule Formulation of Microbiome Ecosystem Therapy

 

  • Independent Data Safety and Monitoring Board (DSMB) recommends continuing study as planned and initiating dosing of fourth patient cohort
  • CIMON clinical trial is evaluating MaaT033, the company’s oral capsule formulation of its lead biotherapeutic (MaaT013), in patients with
    acute myeloid leukemia (AML) following intensive chemotherapy
  • MaaT033 is a donor-derived, standardized, high-richness, high-diversity Microbiome Ecosystem Therapy for oral administration

 

Lyon, France, June 28, 2021 – MaaT Pharma, a clinical-stage biotechnology company focused on developing Microbiome Ecosystem Therapies in oncology, today announced that the Data Safety and Monitoring Board (DSMB) recommended to proceed to the fourth cohort of the dose-finding Phase 1b CIMON clinical trial, without modifications. The DSMB is an independent committee monitoring the progress of the company’s clinical trial and is reviewing safety, tolerability and data quality while the trial is ongoing.

 

Lire le communiqué de presse